Highlights;
- Upling, a Black-owned medical cannabis delivery app, is launching Bud-E, an AI-powered tool to help patients find personalized cannabis strains based on health needs.
- Bud-E uses patient data, medical history, and optional genetics for recommendations, aiming to bring precision to cannabis care.
- It will initially be available in Washington, D.C., and Maryland, with future expansion planned.
[PRESS RELEASE] – ROCKVILLE, Md., Aug. 6, 2025 – Upling, a pioneering high-speed medical cannabis delivery platform, has announced the upcoming launch of Bud-E, an innovative AI-powered cannabis genetics tool. This cutting-edge feature is designed to help patients identify cannabis strains that best align with their unique health needs, marking a significant step forward in personalized cannabis care.
Currently in its beta phase, Bud-E utilizes patient-reported outcomes, medical history, and optional genetic data to provide science-backed strain recommendations through artificial intelligence. A full launch of the tool is set for October.
“By integrating personal health data, patient feedback, and genetic insights, our platform transforms cannabis from a trial-and-error process into a science-driven solution,” said Colin Fraser, founder of Upling, the first Black-owned delivery-focused cannabis app. “Whether someone is managing PTSD, chronic pain, or insomnia, this tool eliminates the guesswork, bringing a precision medicine approach to cannabis care.”
This move positions Upling as one of the first cannabis delivery platforms to integrate advanced personalization technology directly into its user experience. Bud-E aligns with the company’s broader mission of connecting individuals with the right products, information, and support throughout their wellness journey.
Fraser, who founded Upling after witnessing his mother’s struggles accessing medication during her cancer treatment, added, “Implementing AI to curate cannabis consumption is a natural extension of our mission. It removes barriers from the entire process, ensuring patients feel supported from start to finish.”
The launch of Bud-E comes as the legal cannabis industry continues to grow, with delivery services playing a pivotal role. According to the U.S. Department of Health and Human Services, the number of registered medical cannabis patients increased by 37% between 2021 and 2023, driving demand for more accessible, patient-centric services. The Centers for Disease Control and Prevention also reported that nearly 50% of medical cannabis patients prefer home delivery.
Initially, Bud-E will be available to medical cannabis patients in Upling’s Washington, D.C., and Maryland service areas, with plans to expand to adult-use customers in the future.
